Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

🦠🔬 #Covid #Treatment | Clinical efficacy of our anti-COVID antibody, XAV-19, published in Frontiers in Immunology : https://t.co/wOvPC5f7QB 🔍 More info in our press release: https://t.co/1tbzc0k1zN

🦠🔬 #Covid #Traitement | Publication de l’efficacité clinique de notre anticorps anti-COVID, le XAV-19, dans Frontiers in Immunology : https://t.co/wOvPC5f7QB 🔍 Plus d’informations dans notre communiqué : https://t.co/7f4uRXo8lQ

9,058/ Greece, Bulgaria, Romania, Turkey, and Spain Of ~255 with Covid-19, 11.8% were current smokers & 14.9% were past smokers https://t.co/63VUdJFz2F

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19 https://t.co/3PtW9KaqLX #FrontImmunol